Clinical trial
Fentanyl Transdermal Patch With CHADD™ for Breakthrough Pain in Patients With…
NCT00278824 · ZARS Pharma Inc., Industry · Terminated
Key facts
| NCT number | NCT00278824 |
|---|---|
| Title | Fentanyl Transdermal Patch With CHADD™ for Breakthrough Pain in Patients With Moderate to Severe Non-Malignant Pain |
| Official title | A Double-Blind, Placebo-Controlled, Proof-of-Concept Study to Evaluate the Efficacy of CHADD™ Applied Over a Transdermal Fentanyl Patch for the Treatment of Breakthrough Pain in Patients With Moderate to Severe Non-malignant Chronic Pain |
| Lead sponsor | ZARS Pharma Inc., Industry |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Pain |
| Intervention type | Drug |
| Interventions | Matrix Transdermal Fentanyl/CHADD Drug Delivery System, Placebo Patch |
| Enrollment | 109 |
| Start date | Jan 1, 2006 |
| Primary completion | Aug 1, 2006 |
| Completion | Aug 1, 2006 |
| First posted | Jan 18, 2006 |
| Last update posted | Jun 5, 2012 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: